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Abstract
Background: Relationships between improvements in lung function and other clinical outcomes in chronic
obstructive pulmonary disease (COPD) are not documented extensively. We examined whether changes in trough
forced expiratory volume in 1 second (FEV1) are correlated with changes in patient-reported outcomes.
Methods: Pooled data from three indacaterol studies (n = 3313) were analysed. Means and responder rates for
outcomes including change from baseline in Transition Dyspnoea Index (TDI), St. George’s Respiratory
Questionnaire (SGRQ) scores (at 12, 26 and 52 weeks), and COPD exacerbation frequency (rate/year) were tabulated
across categories of ΔFEV1. Also, generalised linear modelling was performed adjusting for covariates such as
baseline severity and inhaled corticosteroid use.
Results: With increasing positive ΔFEV1, TDI and ΔSGRQ improved at all timepoints, exacerbation rate over the
study duration declined (P < 0.001). Individual-level correlations were 0.03-0.18, but cohort-level correlations were
0.79-0.95. At 26 weeks, a 100 ml increase in FEV1 was associated with improved TDI (0.46 units), ΔSGRQ (1.3-1.9
points) and exacerbation rate (12% decrease). Overall, adjustments for baseline covariates had little impact on the
relationship between ΔFEV1 and outcomes.
Conclusions: These results suggest that larger improvements in FEV1 are likely to be associated with larger patient-
reported benefits across a range of clinical outcomes.
Trial Registration: ClinicalTrials.gov NCT00393458, NCT00463567, and NCT00624286
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Introduction
In the absence of other widely accepted and validated
markers for chronic obstructive pulmonary disease
(COPD), lung function measurement, specifically forced
expiratory volume in 1 second (FEV1), has been used as
a global marker for pathophysiological changes [1] and
by regulators in the drug approval process. Conse-
quently, clinical trials for new products in COPD are
typically powered to demonstrate significant improve-
ments in FEV1. However, healthcare professionals are
more likely to be interested in improvements in patient-
reported outcomes such as symptoms and health status,
which may better reflect treatment impact on the
patient. Decision-makers also require evidence to assess
trends across large cohorts of patients.
Several studies have demonstrated a significant rela-
tionship between poor lung function and worsened
health and economic outcomes in patients with COPD
[2-13], but few have investigated whether changes in
lung function associated with an intervention are corre-
lated with changes in such endpoints [12-15]. There is
good evidence that declining lung function leads to wor-
sened patient outcomes, but a surprising lack of evi-
dence that improvements in lung function are correlated
with improvements in symptomatic outcomes.
Indacaterol is a novel, inhaled, ultra-long-acting b2-
agonist. Initial Phase III trials included over 3000
patients, providing a large pooled dataset. We analysed
this dataset in order to examine the relationships
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between change in FEV1 and outcomes including dys-
pnoea, health status, exacerbations and rescue medica-
tion use.
Methods
Study design and treatments
This investigation was a pooled analysis of patient-level
data from three Phase III, randomised studies: Study 1
(INVOLVE [INdacaterol: Value in COPD: Longer term
Validation of Efficacy and safety]) was a double-blind
comparison of indacaterol 300 μg or 600 μg once daily
with formoterol 12 μg twice daily and placebo for 52
weeks; Study 2 (INHANCE [INdacaterol versus tiotro-
pium to Help Achieve New COPD treatment Excel-
lence]) compared double-blind indacaterol 150 μg or
300 μg once daily with placebo and open-label tiotro-
pium 18 μg once daily for 26 weeks; Study 3 (INLIGHT
1 [INdacaterol: efficacy evaLuation usInG 150 μg doses
witH COPD PatienTs]) was a 12-week study comparing
double-blind indacaterol 150 μg once daily with placebo
for 12 weeks. Patients were permitted to continue
inhaled corticosteroid (ICS) monotherapy if the dose
and regimen were stable for 1 month before screening,
and were to remain stable throughout the study;
patients were also permitted rescue salbutamol as
needed. Full details have been reported elsewhere
[16-18]. All studies were conducted in accordance with
the Declaration of Helsinki (1989) and local applicable
laws and regulations. Approval was obtained from the
Institutional Review Board or Independent Ethics Com-
mittee of each participating study centre. All patients
provided written informed consent prior to participating
in each study included in the pooled analysis. All patient
data was anonymised.
Patients
Patients were male or female, aged ≥ 40 years, with a
smoking history of ≥ 20 pack years and a diagnosis of
moderate-to-severe COPD [19]. All patients in whom
trough FEV1 measurements were available both at base-
line and at 12 weeks were included. Patients with
extreme changes from baseline in trough FEV1 (> +500
or < -500 ml) were excluded, as these values were con-
sidered erroneous.
Endpoints
The primary endpoint in all three studies was trough
FEV1 (average of the 23 h 10 min and 23 h 45 min
post-dose value) after 12 weeks of treatment. Trough
FEV1 at baseline was defined as the average of the FEV1
values 50 and 15 min prior to the first dose of study
drug. Trough FEV1 was assessed at the end of Weeks 4,
8 and 12 in all studies, Weeks 16, 20, 24, 28, 36, 44 and
52 in Study 1, and Weeks 16, 21 and 26 in Study 2. In
all studies, spirometry equipment and performance of
spirometric testing was required to be in accordance
with ATS/ERS standards [20].
Secondary endpoints included health status (using the
St George’s Respiratory Questionnaire [SGRQ] [21]), and
dyspnoea (using the Transition Dyspnoea Index [TDI]
[22]; Studies 1 and 2 only). The SGRQ provides scores
between 0 and 100, with higher values indicating greater
impairment. The TDI is inherently a change from base-
line and provides values between -9 and +9, with positive
values indicating improvement. Rescue medication use
(number of puffs of salbutamol) was recorded by patients
in diaries. COPD exacerbations were defined as the onset
or worsening of > 1 respiratory symptom for > 3 conse-
cutive days, requiring intensified treatment (e.g. systemic
steroids, antibiotics, oxygen) and/or hospitalisation or
emergency room visit. Severe exacerbations were those
requiring hospitalisation.
Statistical methods
The primary objective was to examine relationships
between patient-reported outcomes and change from
baseline in trough FEV1 (ΔFEV1) using data summarisa-
tion and model-based analysis. Outcome variables for
both analysis approaches were TDI, change from base-
line in SGRQ (ΔSGRQ), rescue medication use and
exacerbation rates.
For TDI and ΔSGRQ, relationships were examined
with the average of each patient’s ΔFEV1 through the
corresponding week of observation. For rescue medica-
tion use and exacerbations, the average ΔFEV1 over
time on treatment was used.
Data summaries and related inferences
TDI and ΔSGRQ were handled as outcome variables at
12, 24/26 and 52 weeks. Responders were patients who
achieved at least the minimal clinically important differ-
ence (MCID) from baseline (one and four units for TDI
and SGRQ, respectively [21,22]). Daily rescue medica-
tion use was the number of puffs during treatment
divided by the number of days on treatment. Rate of
exacerbations was the number of exacerbations on treat-
ment, normalised to 1 year (365 × number of exacerba-
tions while on treatment/days on treatment).
For each of the timepoints, outcomes and responder
rates for ΔSGRQ and TDI were tabulated across five
categories of ΔFEV1 that were chosen to distribute
patients approximately equally across categories, and
bounded above and below by ± 500 ml. The hypothesis
of equality across categories was tested by the Kruskal-
Wallis test. Correlation coefficients were computed
between observed individual values of ΔFEV1 and the
outcome, and between the category midpoint values of
ΔFEV1 (-275 ml, 0 ml, 100 ml, 200 ml and 375 ml) and
the category mean response of the outcome.
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Model-based analyses
In line with established statistical procedures, general-
ised linear modelling [23,24] was performed to examine
the relationship between ΔFEV1 and each outcome vari-
able. For TDI and ΔSGRQ, observations at all time-
points were modelled together using repeated-measures
multiple regression analyses, assuming constant variance
and an unstructured correlation matrix. Time was
included both as a main effect and in an interaction
with ΔFEV1.
Rescue medication use and exacerbations were mod-
elled as number of puffs and number of exacerbations,
respectively, during time on treatment. Rescue medica-
tion use was modelled using the zero-inflated negative
binomial distribution for likelihood-based model build-
ing, and then the final model was refitted using quasi-
likelihood to report parameter estimates. Exacerbations
were modelled using the negative binomial distribution.
For both, in order to ensure positivity of the modelled
mean response, the logarithm of the mean was repre-
sented as linear in the covariates, and then the mean
was found by taking antilogs.
Other predictor variables were baseline trough FEV1
(continuous), age (continuous), gender (binary), ICS use
(binary: yes or no), treatment (indacaterol, formoterol,
tiotropium or placebo), screening FEV1 measured to
assess reversibility before and after a short-acting b2-
agonist, and before and after a short-acting anticholiner-
gic, world region (Western Europe and the USA, East-
ern Europe and Turkey, Rest-of-World), and time at
risk for exacerbations and rescue medication use. Dis-
ease severity was included as a binary variable, based on
the Global initiative for chronic Obstructive Lung Dis-
ease (GOLD) stages [19]; predominantly GOLD 2 (mod-
erate or less severity including 91% moderate, referred
to subsequently as GOLD 2) versus predominantly
GOLD 3 (severe or greater severity including 98%
severe, referred to as GOLD 3), as measured by per cent
predicted FEV1 at screening after short-acting b2-ago-
nist. The default condition for all models was: baseline
FEV1 of 1.3 l, age 65 years, gender male, GOLD 2, no
ICS use, indacaterol treatment, screening FEV1 before
(and after) reversibility testing of 1.3 l (1.5 l) and Wes-
tern Europe/USA region. All statistical comparisons
were made relative to this combination of covariates,
and unless otherwise stated, these were the values of the
parameters used for predictions by the models.
Model-based inference steps were performed to test
for interactions between ΔFEV1 and the covariates treat-
ment, disease severity, ICS use and world region. For
this purpose, disease severity was represented jointly by
baseline FEV1, the binary severity indicator defined
above, Baseline Dyspnoea Index (BDI) for TDI and base-
line SGRQ for ΔSGRQ. To allow for the possibility of
differing relationships for negative versus positive values
of ΔFEV1, a possible breakpoint at ΔFEV1 = 0 was
tested in each model. The main effects of covariates
were tested for significance according to Wald P values
in the final model, with P < 0.01 judged significant with-
out any adjustments for multiplicity.
For each outcome variable, the improvement in
expected response for an increase in FEV1 from 0 to
100 ml was also computed, based on a model that
excluded treatment effects, to allow for variation in
ΔFEV1 between, as well as within, treatments.
Results
In total, 3313 patients were included in the analysis.
Patient demographic and clinical characteristics are pre-
sented in Table 1. Age, pre- and post-bronchodilator
FEV1 and body mass index were well balanced across
studies. Study 1 included more males, patients taking
ICS and patients with slightly lower per cent predicted
FEV1 and reversibility.
Data summaries and related inferences
The distribution of average ΔFEV1 responses by time-
point is shown in Table 2, both as frequencies within
ΔFEV1 categories and as percentiles of distributions.
Median values ranged from 75 to 94 ml. Approximately
5% of observations were excluded due to extreme
ΔFEV1 (± 500 ml) at any timepoint; 0.7% observations
(24/3313) were less than -500 ml and 4.1% (137/3313)
were greater than 500 ml at Week 12.
All relationships between ΔFEV1 and outcomes were
statistically significant, except for severe exacerbations
(Table 3). Individual-level correlations were weak (0.03-
0.18), reflecting the large variability in outcomes; how-
ever, cohort-level correlations were stronger (0.79-0.95).
When outcome means were plotted versus ΔFEV1 mid-
points, there were clear trends towards greater improve-
ment in outcomes with increasing ΔFEV1, particularly
for positive ΔFEV1 (Figure 1). Responder rates, in terms
of TDI and ΔSGRQ, followed a similar pattern to the
mean outcomes (Table 4).
Model-based results
The plots of curves fitted from the model-based analysis
for each outcome variable versus ΔFEV1 are presented
in Figures 2a-d. For TDI and ΔSGRQ, the significant
breakpoints at zero are evident in the changes of slope
in the fitted lines. For rescue medication and exacerba-
tions the breakpoints were not significant. The fitted
curves for rescue medication and exacerbations are lin-
ear on logarithmic scales, so appear nonlinear on the
scales of these plots.
ΔFEV1 was significantly correlated with TDI score (P
< 0.0001). A significant breakpoint in the fitted lines is
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seen at zero; the slope was significantly shallower for
negative ΔFEV1 compared with positive ΔFEV1 (P =
0.003 for the difference between slopes). The slope of
the relationship (determining the magnitude of change
in outcome for a given improvement in ΔFEV1) was not
significantly affected by treatment, baseline severity, ICS
use or world region. Hence, the overall model-predicted
increase in TDI for a 100 ml increase in ΔFEV1 was the
same for all combinations of covariates, and estimated
to be 0.46 at Week 24/26. Although the slope of the
relationship with ΔFEV1 was the same for all covariates,
the intercept, that is, the TDI corresponding to zero
change in FEV1, was not. For a given ΔFEV1, patients
with lower baseline FEV1, lower BDI, using ICS or on
placebo, had significantly lower values of TDI, while
those from Eastern Europe/Turkey and Rest-of-World
regions had significantly higher values. When covariates
representative of patients who were less severe were
inputted into the model (i.e., GOLD 2, no ICS and base-
line FEV1 of 1.595 l), the model-predicted TDI for a
zero and +100 ml change in FEV1 was 1.98 and 2.44,
respectively. For more severe patients (i.e., GOLD 3, ICS
and baseline FEV1 of 0.95 l), the model-predicted TDI
for patients with zero and +100 ml change in FEV1 was
-0.20 and 0.26, respectively.
There was a significant correlation between ΔSGRQ
and ΔFEV1 (P < 0.0001). As with TDI, the slope of the
relationship between ΔSGRQ and ΔFEV1 was
Table 1 Baseline characteristics of study participants included in the analysis
Study 1 INVOLVE [16] Study 2 INHANCE [17] Study 3 INLIGHT 1 [18] Total
n 1377 1575 361 3313
Age, years 64 (8) 64 (9) 63 (10) 64 (9)
Male/female, % 78/22 63/37 52/48 69/31
Body mass index, kg/m2 27 (5) 27 (6) 28 (7) 27 (6)
FEV1, % predicted* 53 (14) 56 (14) 55 (14) 55 (14)
FEV1/FVC, %* 51 (10) 53 (10) 53 (10) 52 (10)
Pre-bronchodilator FEV1, l 1.35 (0.43) 1.33 (0.49) 1.34 (0.51) 1.34 (0.47)
Post-bronchodilator FEV1, l* 1.52 (0.47) 1.50 (0.50) 1.51 (0.52) 1.51 (0.49)
Reversibility, %* 13.2 (13.4) 15.5 (15.9) 16.0 (18.7) 14.6 (15.3)
ICS use yes/no, % 55/45 38/62 32/68 45/55
Smoker/ex-smoker, % 40/60 44/56 52/48 43/57
BDI score 6.6 (2.2) 6.5 (2.3) NA 6.5 (2.2)
SGRQ total score 44 (18) 45 (18) 49 (19) 45 (18)
Treatments
Placebo, n 322 311 176 809
Indacaterol 75 μg, n 0 67 0 67
Indacaterol 150 μg, n 0 346 185 531
Indacaterol 300 μg, n 363 357 0 720
Indacaterol 600 μg, n 344 68 0 412
Formoterol 12 μg, n 348 75 0 423
Tiotropium 18 μg, n 0 351 0 351
Data are mean (standard deviation) unless otherwise stated. *Measured 30 min after salbutamol 400 μg inhalation. Reversibility was calculated as the difference
between the pre- and post-bronchodilator values of FEV1 (in l) as a percentage of the pre-bronchodilator value; BDI, Baseline Dyspnoea Index; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; INVOLVE, INdacaterol: Value in COPD: Longer term Validation of Efficacy and
safety; INHANCE, INdacaterol versus tiotropium to Help Achieve New COPD treatment Excellence; INLIGHT, INdacaterol: efficacy evaLuation usInG 150 μg doses
with COPD PatienTs; NA, not available; SGRQ, St George’s Respiratory Questionnaire.
Table 2 Summary information for averages of ΔFEV1
Number of observations in intervals defined by ml ranges Percentiles* of observations
Average of
ΔFEV1
n <
-500
-500,
-50
-50,
50
50,
150
150,
250
250,
500
>
500
Minimum 5% 25% 50% 75% 95% Maximum
Week 4-12 3313 24 623 695 717 563 554 137 -1180 -198 -20 94 220 466 1966
Week 4-24/26 2389 16 478 476 550 388 377 104 -1148 -203 -30 88 214 474 1782
Week 4-52 1169 6 292 218 273 165 168 47 -755 -223 -52 75 201 464 1607
On treatment 3313 24 708 662 751 536 501 131 -1180 -213 -32 82 208 467 1966
*For example, when averaging over time on treatment, the minimum average ΔFEV1 was -1180 ml and the maximum was 1966 ml; between these points, 5%
observations were less than or equal to -213 ml and half were less than or equal to 82 ml; ΔFEV1, change from baseline in trough forced expiratory volume in 1
second.
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significantly shallower for negative ΔFEV1 (P = 0.002 for
the difference between slopes). The slope of the rela-
tionship with improvement in FEV1 was not significantly
affected by treatment, ICS use, or world region, but it
was steeper for patients in GOLD 3, and with baseline
FEV1 0.95 l compared with GOLD 2 and baseline FEV1
1.595 l (P = 0.004). For an increase of ΔFEV1 of 100 ml,
the model predicted a change in SGRQ of -1.3 for
GOLD 2 and -1.9 for GOLD 3 patients at Week 24/26.
Patients with worse baseline FEV1, with worse baseline
SGRQ, using ICS or on placebo, had significantly higher
ΔSGRQ, whereas patients from Eastern Europe/Turkey
and Rest-of-World regions had significantly lower
ΔSGRQ at Week 24/26. For GOLD 2 patients, who had
used no ICS and had baseline SGRQ of < 31, the
model-predicted improvement in SGRQ at Week 26 for
a zero and +100 ml change in FEV1 was -1.6 and -2.9,
respectively. Similarly, for GOLD 3 patients who had
used ICS and had baseline SGRQ of > 58, the model-
predicted improvement in SGRQ at Week 24/26 was
-0.9 and -2.8, respectively.
ΔFEV1 was significantly correlated with rescue medi-
cation use (P < 0.0001). Treatment, baseline severity,
ICS use or world region, did not significantly affect the
slope of the relationship, and the slope did not change
significantly between negative and positive ΔFEV1.
Hence, for all combinations of covariates, an increase of
100 ml in ΔFEV1 is predicted to yield the same 10%
reduction in rescue medication use. Patients with lower
baseline FEV1, male patients, those with higher baseline
medication usage or more severe disease, using ICS or
on placebo or tiotropium, had significantly higher rates
of rescue medication usage. Younger patients (< 65
years) had almost significantly higher rates (P = 0.012,
versus the defined significance level of P < 0.01). For
GOLD 2 patients not receiving ICS, the predicted daily
number of puffs of rescue medication for a zero and
+100 ml ΔFEV1 was 0.89 and 0.80, respectively, and
1.83 and 1.64 for those in GOLD 3 and using ICS.
ΔFEV1 was significantly correlated with exacerbations
(P = 0.002). Treatment, baseline severity, ICS use or
world region, did not significantly affect the slope of the
relationship. Furthermore, the slope did not change sig-
nificantly between negative and positive ΔFEV1. Hence,
for all combinations of covariates, an increase of 100 ml
in ΔFEV1 is predicted to yield the same 12% decrease in
exacerbations. Patients with lower baseline FEV1 and
patients using ICS had significantly higher rates of
exacerbations. Patients from the Eastern Europe/Turkey
region had significantly lower rates of exacerbations.
The model estimate for the annual rate of exacerbations
for patients with a zero and +100 ml ΔFEV1 were 0.29
and 0.25, respectively, for GOLD 2 patients not using
ICS; and 1.28 and 1.12, respectively, for patients in
GOLD 3 and using ICS. As in the summary analysis, the
rate of severe exacerbations requiring hospitalisation was
not significantly correlated with ΔFEV1 (P = 0.3).
Discussion
Our analyses show that improvement in FEV1 is signifi-
cantly related to changes in the patient-reported out-
comes TDI, SGRQ, exacerbation rate and rescue
medication use over 12-52 weeks of treatment. These
relationships were significant at both an individual and
Table 3 Outcome means by average ΔFEV1 category, P values for associations between average ΔFEV1 and outcome,
and correlations at individual and cohort levels
Average
ΔFEV1 (ml)
Category
midpoint
value of
ΔFEV1
(ml)
Withdrawal
rate* (%
patients)
TDI at
12
weeks
(n =
2781)
TDI at
24/26
weeks
(n =
2208)
TDI at
52
weeks
(n =
1099)
ΔSGRQ
at 12
weeks
(n =
3141)
ΔSGRQ
at 24/
26
weeks
(n =
2215)
ΔSGRQ
at 52
weeks
(n =
1115)
Rescue
medication
mean puffs per
day (over study
duration) (n =
3158)
Exacerbation
rate (per
year) (n =
3158)
Severe
exacerbation
rate (per
year) (n =
3158)
-500, -50 -275 11.2 1.44 1.57 1.24 -3.15 -4.70 -2.21 2.46 0.63 0.059
-50, 50 0 9.0 1.31 1.39 1.92 -3.17 -3.81 -3.03 2.57 0.58 0.065
50, 150 100 10.1 1.79 1.97 1.65 -3.84 -4.74 -4.22 2.10 0.61 0.057
150, 250 200 10.2 2.12 2.23 2.23 -5.84 -6.34 -6.70 1.80 0.51 0.048
250, 500 375 6.7 2.68 3.03 3.27 -7.38 -7.29 -9.06 1.66 0.38 0.021
P value
(Kruskal-
Wallis)
< 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.1
Correlation,
individual
level
0.15 0.14 0.18 -0.12 -0.07 -0.16 -0.11 -0.06 -0.03
Correlation,
cohort level
0.90 0.88 0.92 -0.90 -0.79 -0.95 -0.88 -0.89 -0.81
*Non-completers in all studies categorised by ΔFEV1 at Day 2; ΔFEV1, change from baseline in trough forced expiratory volume in 1 second; TDI, Transition
Dyspnoea Index; ΔSGRQ, change from baseline in St George’s Respiratory Questionnaire
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population level, although correlations were much stron-
ger in the population-based analyses.
Few studies have examined the relationship between
change in FEV1 and change in outcomes. However, our
results are consistent with analyses of patients from the
3-year EUROSCOP (The European Respiratory Society
Study on Chronic Obstructive Pulmonary disease) study,
in which an improvement of 100 ml in FEV1 was asso-
ciated with a 4% reduction in dyspnoea in males [13],
and a 16-week clinical study, in which a significant, but
weak correlation between change in FEV1 and change in
SGRQ score was demonstrated (r = 0.33, P = 0.001)
[14]. Further, a recent systematic review of 22 studies
found that 100 ml increase in FEV1 was associated with
a statistically significant reduction in SGRQ of 2.5 [15].
However, to our knowledge, the current analysis is the
largest and most comprehensive to investigate the corre-
lation between change in FEV1 and change in outcomes
Figure 1 Outcome means in ΔFEV1 categories versus category midpoint value. Plots show data with Loess smooth curves superimposed.
ΔFEV1, change from baseline in trough forced expiratory volume in 1 second; TDI, Transition Dyspnoea Index; ΔSGRQ, change from baseline in
St George’s Respiratory Questionnaire.
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using individual patient data from studies of similar
design. This provides a relatively homogeneous popula-
tion for analysis, compared with study-level meta-
analyses.
We demonstrated that a 100 ml increase in trough
FEV1 (a magnitude of change with perceptible effects
[25]) was associated with a 0.46-unit increase in TDI
and a 1.3- to 1.9-unit improvement in SGRQ after a 24/
26-week treatment period and, over 12-52 weeks of
treatment, a 10% decrease in daily rescue medication
use and a 12% decrease in the annual exacerbation rate.
In general, we found that treatment, baseline severity,
concomitant ICS use and world region, did not affect
the slope of the relationship between outcome and
change in FEV1, except for ΔSGRQ where more severe
COPD, as characterised by a lower FEV1 and a higher
SGRQ at baseline, was associated with a steeper slope,
compared with less severe COPD. This is consistent
with results from the 3-year TORCH (TOwards a Revo-
lution in COPD Health) study, in which trends to
greater improvement in SGRQ with worsening GOLD
severity were noted with active treatments [26].
Although severe exacerbations showed a trend toward
greater reductions with increasing ΔFEV1, the relation-
ship was not statistically significant. While the observed
12% reduction in overall exacerbation rate for an
improvement of 100 ml in FEV1 was comparable with
previously published data [11], the studies included in
our analysis were not powered to show an effect on
exacerbations, and did not specifically recruit patients at
risk of exacerbations.
We found inconsistent effects of different treatments
across individual outcomes, perhaps due to patient
numbers in sub-categories being too low to demonstrate
consistent differences for individual treatments across
all outcomes. However, our analysis did demonstrate
that the relationship between ΔFEV1 and outcome
appeared to be the same, regardless of treatment arm.
Similarly, baseline severity, ICS use and world region
were assessed as main effects, as well as for their
potential influence on the effect of ΔFEV1. Although
numbers of patients in GOLD 4 (as well as GOLD 1)
were too small to make any inferences, patients predo-
minantly in GOLD 3 at baseline, and those using ICS,
consistently exhibited significantly worse outcomes.
Indeed, the variability in baseline severity and ICS use
are likely to have been major contributors to the large
variability in observed outcomes.
The relationships between outcomes and ΔFEV1 may
differ between negative and positive ΔFEV1, and for this
reason, the models included a possible breakpoint at
zero in the relationship slope. The inclusion of this
breakpoint was found to be significant for TDI and
ΔSGRQ, suggesting that baseline severity and other
included covariates could not explain the observed
behaviour fully. These results may have been influenced
by differences in withdrawal rates between categories
[27], since the highest withdrawal rate was in those with
a negative change in FEV1, although differences between
groups were minimal. The inclusion of a breakpoint was
not significant for rescue medication and exacerbations,
even though Figure 1 may have anticipated its impor-
tance, especially for exacerbations. The large variability
and count nature of the data for rescue medication and
exacerbations may have caused ‘Type-2’ statistical errors,
i.e., failure to find the true breakpoints to be significant.
We found that zero change in FEV1 was associated
with significant positive improvements in TDI and
SGRQ. Additionally, while a greater proportion of
patients achieved the MCID for TDI and SGRQ as
ΔFEV1 increased, our results indicated that as many as
50% patients responded, irrespective of ΔFEV1, possibly
an effect of clinical trial participation seen consistently
in the placebo limb of clinical trials [28-30].
We constructed the models in our analysis using
ΔFEV1 as a predictor, and the other outcome measures
as the response variables, based on the results of a care-
fully-controlled series of clinical trials. However, ΔFEV1
was as much a response as was the outcome, so ΔFEV1
was not an ‘independent’ variable controlled as part of
Table 4 Responder rates* for TDI† and ΔSGRQ† by average ΔFEV1 category
Average
ΔFEV1
(ml)
Category
midpoint
value of ΔFEV1
(ml)
TDI at 12
weeks %
responders (n
= 2781)
TDI at 24/26
weeks %
responders (n =
2208)
TDI at 52
weeks %
responders (n
= 1099)
ΔSGRQ at 12
weeks %
responders (n =
3141)
ΔSGRQ at 24/26
weeks %
responders (n =
2215)
ΔSGRQ at 52
weeks %
responders (n =
1115)
-500, -50 -275 50 51 45 42 49 41
-50, 50 0 48 49 53 46 45 45
50, 150 100 54 57 50 48 48 49
150, 250 200 59 60 58 53 59 54
250, 500 375 66 69 69 56 57 65
*Responders were patients who achieved at least the minimal clinically important difference (MCID; one and four units for TDI and ΔSGRQ, respectively); TDI,
Transition Dyspnoea Index; ΔSGRQ, change from baseline in St George’s Respiratory Questionnaire; ΔFEV1, change from baseline in trough forced expiratory
volume in 1 second.
†For the outcomes, each row contains approximately 20% of the column’s indicated n, as in the left half of Table 2
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Figure 2 Outcomes versus ΔFEV1: curves fitted from model-based analysis. SGRQ and TDI data is for Week 24/26. Exacerbations are
reported counts normalised to 1 year. Rescue medication use is reported numbers of puffs normalised to 1 day. For plotting predicted curves,
‘moderate’ refers to baseline FEV1 1.595 l (third quartile of observed values) and GOLD 2 (moderate or less [19]); ‘severe’ refers to baseline FEV1
0.95 l (first quartile of observed values) and GOLD 3 (severe or greater [19]). For TDI, ‘moderate’ and ‘severe’ refer to BDI at quartiles 2 and 1,
respectively. For ΔSGRQ, ‘moderate’ and ‘severe’ refer to baseline SGRQ at quartiles 31.3 and 58.13, respectively; ΔFEV1, change from baseline in
trough forced expiratory volume in 1 second; ΔSGRQ, change from baseline in St George’s Respiratory Questionnaire; TDI, Transition Dyspnoea
Index; GOLD, Global initiative for chronic Obstructive Lung Disease; BDI, Baseline Dyspnoea Index; ICS, inhaled corticosteroid.
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the experimental design. There may have been further
confounders that simultaneously affected how both
ΔFEV1 and the outcome responded to treatment. The
fitted models therefore describe the observed relation-
ships under the conditions of a clinical trial, but do not
provide a definitive answer as to whether there is a cau-
sal relationship between ΔFEV1 and the outcomes.
The studies included in our analysis were powered on
the spirometric endpoint FEV1, which is required by
regulatory agencies for the approval of bronchodilators,
and is included in the majority of treatment guidelines.
For this reason we made FEV1 the focus of our analysis.
Other physiological parameters such as inspiratory capa-
city may have stronger correlations with dyspnoea [31].
However data for these parameters were not available
from our dataset and further research is needed to
investigate such correlations in large numbers of
patients.
Conclusions
It is commonly stated that spirometry does not fully
capture the impact of COPD on a patient’s health [32].
Our analysis of a large cohort of patients has demon-
strated that in individual subjects, change in FEV1 is a
significant, albeit relatively weak predictor of improve-
ment in patient-reported outcomes. However, the cur-
rent analysis also shows that, at a population level,
improvements in FEV1 with long-acting bronchodilator
therapy are strongly correlated with improvements in
dyspnoea, health status and exacerbations. This suggests
that interventions which significantly improve FEV1 are
also likely to be associated with improved clinical and
patient-reported outcomes.
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